Clearmind Medicine Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type other
SEC Category Non-accelerated filerEmerging growth company
State of Incorporation Canada (Federal Level)
Business Address 101-1220 WEST 6TH AVENUE, VANCOUVER, BRITISH COLUMBIA, Z4, V6H1A5
Mailing Address 101-1220 WEST 6TH AVENUE, VANCOUVER, BRITISH COLUMBIA, Z4, V6H1A5
Phone 972-54-5704749
Fiscal Year End 1031
EIN 000000000
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 6-K Foreign company current report | February 11, 2026 | View on SEC |
| 6-K Foreign company current report | February 9, 2026 | View on SEC |
| 6-K Foreign company current report | February 6, 2026 | View on SEC |
| 6-K Foreign company current report | February 4, 2026 | View on SEC |
| 6-K Foreign company current report | February 3, 2026 | View on SEC |
| 20-F Foreign company annual report | January 20, 2026 | View on SEC |
| 6-K Foreign company current report | January 14, 2026 | View on SEC |
| 6-K Foreign company current report | December 31, 2025 | View on SEC |
| 6-K Foreign company current report | December 29, 2025 | View on SEC |
| 6-K Foreign company current report | December 16, 2025 | View on SEC |
Annual Reports
20-F January 20, 2026
- Successfully completed pre-clinical studies for CMND-100, demonstrating promising safety and efficacy in animal models.
- Expanded intellectual property portfolio by securing two new patents and established a strategic partnership with a leading research institution.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.